Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated November 10, 2021, serves as a current report for Relay Therapeutics, Inc. (RLAY), a biopharmaceutical company incorporated in Delaware. The filing announces the release of financial results for the quarter ended September 30, 2021. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
No specific material changes versus the prior comparable period are detailed in the body of this Form 8-K. The document functions as a notification that the quarterly results have been announced and are available in the attached exhibit.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors within the main text. It includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2021 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or pipeline milestones mentioned in the press release.
- Confirm the status of the company's emerging growth company election and any related accounting standard transitions.